Clinical trial • Phase I • Other

DOTA-Cys-ATH001 labelled with gallium-68 ([68Ga]) for Metabolic dysfunction-associated steatohepatitis (MASH) | Crohn's disease | Primary sclerosing cholangitis

Phase I trial of DOTA-Cys-ATH001 labelled with gallium-68 ([68Ga]) for Metabolic dysfunction-associated steatohepatitis (MASH) | Crohn's disease | Primary…

Overview

Trial Therapeutic Area
Other
Trial Disease
Metabolic dysfunction-associated steatohepatitis (MASH) | Crohn's disease | Primary sclerosing cholangitis
Trial Stage
Phase I
Drug Modality
Radiopharmaceutical

Key dates

Initial CTIS Submission Date
15-02-2024
First CTIS Authorization Date
07-05-2024

Trial design

Phase I trial across 3 sites in Sweden.

Target Sample Size
30

Eligibility

Recruits 30 No vulnerable population selected (isVulnerablePopulationSelected=false). Consent/assent handling not specified in the record..

Vulnerable Population
No vulnerable population selected (isVulnerablePopulationSelected=false). Consent/assent handling not specified in the record.

Recruitment

Planned Sample Size
30
Recruitment Window Months
21

Geography

Total Number Of Sites
3
Total Number Of Participants
30

Sweden

Earliest CTIS Part Ii Submission Date
16-04-2024
Latest Decision Or Authorization Date
23-01-2026
Processing Time Days
647
Number Of Sites
3
Number Of Participants
30

Sites

Site Name
Uppsala University Hospital
Department Name
Section of Gastroenterology/Hepatology
Principal Investigator Name
Johan Vessby
Principal Investigator Email
johan.vessby@akademiska.se
Contact Person Name
Johan Vessby
Contact Person Email
johan.vessby@akademiska.se
Site Name
CTC Clinical Trial Consultants AB
Department Name
CTC
Principal Investigator Name
Sonia Jonsson
Principal Investigator Email
sonia.jonsson@ctc-ab.se
Contact Person Name
Sonia Jonsson
Contact Person Email
sonia.jonsson@ctc-ab.se
Site Name
CTC Clinical Trial Consultants AB
Department Name
CTC
Principal Investigator Name
Erik Rein-Hedin
Principal Investigator Email
erik.rein-hedin@ctc-ab.se
Contact Person Name
Erik Rein-Hedin
Contact Person Email
erik.rein-hedin@ctc-ab.se

Sponsor

Primary sponsor

Full Name
Antaros Medical AB
Organisation Type
Pharmaceutical company
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
[68Ga]Ga-DOTA-Cys-ATH001
Active Substance
DOTA-Cys-ATH001 labelled with gallium-68 ([68Ga])
Modality
Radiopharmaceutical
First In Human
Yes

Related trials

Other published trials that may interest you.